Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Imaging the role of GABA in movement disorders.

Boecker H.

Curr Neurol Neurosci Rep. 2013 Oct;13(10):385. doi: 10.1007/s11910-013-0385-9. Review.

PMID:
23990356
2.

The role of positron emission tomography imaging in movement disorders.

Bohnen NI, Frey KA.

Neuroimaging Clin N Am. 2003 Nov;13(4):791-803. Review.

PMID:
15024962
3.
4.

Sensorimotor integration in movement disorders.

Abbruzzese G, Berardelli A.

Mov Disord. 2003 Mar;18(3):231-40. Review.

PMID:
12621626
5.

Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.

Allen KL, Waldvogel HJ, Glass M, Faull RL.

J Chem Neuroanat. 2009 Jul;37(4):266-81. doi: 10.1016/j.jchemneu.2009.02.001. Epub 2009 Feb 21.

PMID:
19481011
6.

Understanding the pathophysiology of essential tremor through advanced neuroimaging: a review.

Bhalsing KS, Saini J, Pal PK.

J Neurol Sci. 2013 Dec 15;335(1-2):9-13. doi: 10.1016/j.jns.2013.09.003. Epub 2013 Sep 10. Review.

PMID:
24060292
7.

GABAergic circuits in the basal ganglia and movement disorders.

Galvan A, Wichmann T.

Prog Brain Res. 2007;160:287-312. Review.

PMID:
17499121
8.

From ion currents to genomic analysis: recent advances in GABAA receptor research.

Rabow LE, Russek SJ, Farb DH.

Synapse. 1995 Nov;21(3):189-274. Review.

PMID:
8578436
10.

The anatomical basis of dystonia: current view using neuroimaging.

Lehéricy S, Tijssen MA, Vidailhet M, Kaji R, Meunier S.

Mov Disord. 2013 Jun 15;28(7):944-57. doi: 10.1002/mds.25527. Review.

PMID:
23893451
11.

GABAergic neurotransmission in globus pallidus and its involvement in neurologic disorders.

Chen L, Yung WH.

Sheng Li Xue Bao. 2004 Aug 25;56(4):427-35. Review.

12.

GABA as a trophic factor for developing monoamine neurons.

Lauder JM, Liu J, Devaud L, Morrow AL.

Perspect Dev Neurobiol. 1998;5(2-3):247-59. Review.

PMID:
9777640
13.

GABA receptor agonists: pharmacological spectrum and therapeutic actions.

Bartholini G.

Med Res Rev. 1985 Jan-Mar;5(1):55-75. Review.

PMID:
2984490
14.
15.

Neurochemical substrates of rigidity and chorea in Huntington's disease.

Storey E, Beal MF.

Brain. 1993 Oct;116 ( Pt 5):1201-22.

PMID:
7693298
16.
17.

Impaired brain GABA in focal dystonia.

Levy LM, Hallett M.

Ann Neurol. 2002 Jan;51(1):93-101.

PMID:
11782988
18.

Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.

Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Pérez-Rosado A, Manzanares J, Ramos JA, Fernández-Ruiz J.

Synapse. 2002 Apr;44(1):23-35.

PMID:
11842443
19.

The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake.

Romero J, de Miguel R, Ramos JA, Fernández-Ruiz JJ.

Life Sci. 1998;62(4):351-63.

PMID:
9450507
20.

The neuropathology of GABA neurons in extrapyramidal disorders.

Lloyd KG.

J Neural Transm Suppl. 1980;(16):217-27. Review.

PMID:
6448916

Supplemental Content

Support Center